With this in mind, in the last decade, many efforts have been made to use other treatments for cancer in combination with tuberculosis to increase the effectiveness of CAR-T cell therapy, especially in solid tumors. The combination therapy results have promising consequences for tumor regression an...
Cancer treatments such as chemotherapy and radiation are designed to kill cancer cells, shrink tumors, and prevent the spread of the disease. With advances in the understanding of how genes work, scientists have begun using gene therapy to correct the faulty DNA that causes cancer cells to grow...
New treatments for cancer and heart disease on the horizon?CancerHeart diseaseJNKsApoptosisSignal transductionKingman S.doi:10.1016/S1359-6446(00)01519-1Kingman SElsevier LtdDrug Discovery Today
In recent years, CAR engineering of natural killer (NK) cells has gained considerable traction due to the unique biological properties of NK cells that make them highly attractive cells for cancer immunotherapy. NK cells are innate immune cells which mediate cytotoxicity against cancerous and virally...
The COVID-19 pandemic brought mRNA vaccines into the limelight. But the technology may also prove to be a powerful weapon against hard-to-treat cancers.
T cell therapy are in development for the treatment of AML. As such, chimeric antigen receptor (CAR) T cells are engineered T cells which have been developed in recent years as a breakthrough in cancer therapy. Interestingly, CAR T cells are effective against both solid tumors and ...
To help solve this problem, my research group has built designerartificial cellson a chip the size of a postage stamp. These artificial cells mimic how cells degrade during cancer. This makes it possible to test new drugs early indrugdiscovery (the process of drug development), and see whethe...
Despite the development of a new boxed warning, CAR T-cell therapy remains a promising avenue for cancer treatment. Continued research efforts should be focused on refining CAR T-cell engineering, optimizing patient selection criteria, and developing novel strategies to mitigate trea...
[2]. Through the stimulation of the immune system, cancer immunotherapies have shown potential to induce long-term remission and offer a durable treatment option for cancer patients. Additionally, cancer immunotherapy may also have fewer side effects than traditional cancer treatments, which can lead ...
USFDA has approved brexucabtagene autoleucel (Tecartus, KTE-X19), a novel CAR T-cell therapy to be used in patients with MCL who have not responded to previous treatments or have relapsed. The FDA approved this new treatment depending on the outcomes of the ZUMA-2 clinical trial. Serious...